合约开发和生产组织 (CDMO) 市场分析及预测至 2035 年：类型、产品类型、服务、技术、应用、形式、最终用户、流程和阶段

预计到2034年，医药合约研发生产市场规模将从2024年的1,765亿美元成长至3,357亿美元，年复合成长率约为6.8%。医药合约研发生产市场涵盖外部合作伙伴为製药公司提供的服务，包括药物研发、生产和包装。该市场有助于提高成本效益和扩充性，使企业能够专注于其核心竞争力。对学名药、生物製药和个人化医疗的需求不断增长是推动市场成长的主要因素，而技术进步则提高了产能和合规性。

受药物研发和生产外包需求不断增长的推动，医药合约研发生产市场正经历强劲成长。研发领域，尤其是製剂和製程研发，是推动市场成长的主要动力，这主要得益于对专业知识和先进技术的需求。生产服务，特别是生物製药和生物相似药的生产，紧随其后，反映出市场对复杂生物製药的日益关注。在这些领域中，小分子药物研发子领域表现最为突出，受益于市场对学名药的持续需求。同时，包括单株抗体和重组蛋白在内的大分子药物生产子领域预计将呈现第二高的成长率，这主要得益于生物技术的进步。数位化技术和自动化在生产流程中的应用，有助于提高效率和品管。製药公司与合约服务供应商之间的策略联盟和合作，正在推动进一步的创新和市场扩张。

医药合约研发生产组织（CDMO）市场正经历市场份额、定价和新产品上市方面的动态变化。主要企业正利用创新技术提升自身价值主张，进而形成充满挑战却又机会无限的竞争格局。对成本效益高、生产效率高的流程的关注，推动了新产品的涌现。各公司正策略性地调整定价模式，以满足医药产业不断变化的需求，力求扩大市场占有率。市场对专业服务的强劲需求是其成长和创新的主要驱动力。该行业的竞争标竿分析显示，市场由少数几家主要企业主导，而规模较小的企业则努力透过专业服务开闢利基市场。监管的影响至关重要，严格的合规要求塑造企业的策略。北美和欧洲对监管标准有着显着的影响力，进而影响全球市场动态。亚太地区的新兴市场由于有利的政策和基础设施投资，正经历日益活跃的市场环境。併购透过重塑市场边界和刺激创新，进一步加剧了竞争。这项综合分析强调了战略灵活性和监管合规性在驾驭复杂的製药行业中的重要性。

主要趋势和驱动因素：

受生物製药和生物相似药需求不断增长的推动，医药合约研发生产市场正经历强劲成长。这一趋势源自于慢性病盛行率的上升以及对创新治疗方案的需求。生物製药公司正将研发和生产流程外包，以提高效率并专注于核心竞争力。另一个关键趋势是个人化医疗的兴起，这需要专业的生产能力。契约製造製造商正在投资先进技术，以支援小批量、高精度生产。对品质和法规遵从性的日益重视也是一个关键驱动因素，促使企业与经验丰富的契约製造合作，以应对复杂的监管环境。此外，医药供应链的全球化也为合约研发生产力机构（CDMO）在新兴市场拓展业务创造了机会。随着製药公司寻求降低成本和提高柔软性，与契约製造製造商建立策略合作伙伴关係变得日益重要。这些合作正在缩短新药上市时间，从而推动市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

• 宏观经济分析
• 市场趋势
• 市场驱动因素
• 市场机会
• 市场限制
• 复合年均成长率：成长分析
• 影响分析
• 新兴市场
• 技术蓝图
• 战略框架

第四章 细分市场分析

• 市场规模及预测：依类型
  • 小分子药物
  • 生物製药
  • 先进疗法药物
• 市场规模及预测：依产品划分
  • 原料药（API）
  • 最终剂型（FDF）
  • 中级
• 市场规模及预测：依服务划分
  • 配方开发
  • 製程开发
  • 分析服务
  • 临床生产
  • 商业生产
  • 包装
• 市场规模及预测：依技术划分
  • 冷冻干燥
  • 喷雾干燥
  • 奈米科技
  • 连续製造
• 市场规模及预测：依应用领域划分
  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 感染疾病
  • 免疫学
  • 呼吸系统
• 市场规模及预测：依类型
  • 固态的
  • 液体
  • 半固态
• 市场规模及预测：依最终用户划分
  • 製药公司
  • 生技公司
  • 研究所
• 市场规模及预测：依製程划分
  • 大量生产
  • 连续製造
• 市场规模及预测：依发展阶段划分
  • 临床前阶段
  • 临床
  • 商业的

第五章 区域分析

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地区
• 亚太地区
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲
  • 台湾
  • 亚太其他地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 其他欧洲地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 撒哈拉以南非洲
  • 其他中东和非洲地区

第六章 市场策略

• 需求与供给差距分析
• 贸易和物流限制
• 价格、成本和利润率趋势
• 市场渗透率
• 消费者分析
• 法规概述

第七章 竞争讯息

• 市场定位
• 市场占有率
• 竞争基准
• 主要企业的策略

第八章 公司简介

• Catalent
• Lonza
• Recipharm
• Patheon
• Wu Xi App Tec
• Siegfried Holding
• Piramal Pharma Solutions
• Fujifilm Diosynth Biotechnologies
• Cambrex Corporation
• Almac Group
• Vetter Pharma
• Boehringer Ingelheim Bio Xcellence
• Ajinomoto Bio-Pharma Services
• Samsung Biologics
• Thermo Fisher Scientific
• Corden Pharma
• Fareva
• Hovione
• AMRI
• Baxter Bio Pharma Solutions

第九章：关于我们

Pharmaceutical Contract Development and Manufacturing Market is anticipated to expand from $176.5 billion in 2024 to $335.7 billion by 2034, growing at a CAGR of approximately 6.8%. The Pharmaceutical Contract Development and Manufacturing Market encompasses services provided by external partners to pharmaceutical companies, including drug development, manufacturing, and packaging. This market supports cost efficiency and scalability, allowing firms to focus on core competencies. Increasing demand for generic drugs, biologics, and personalized medicine drives growth, with technological advancements enhancing production capabilities and regulatory compliance.

The Pharmaceutical Contract Development and Manufacturing Market is experiencing robust growth, propelled by the increasing demand for outsourcing in drug development and manufacturing. The development segment, particularly in drug formulation and process development, is leading the market, driven by the need for specialized expertise and advanced technologies. Manufacturing services, especially in the production of biologics and biosimilars, follow closely, reflecting the growing focus on complex biologic drugs. Within these segments, the small molecule development sub-segment is a top performer, benefiting from the enduring demand for generic drugs. Meanwhile, the large molecule manufacturing sub-segment, encompassing monoclonal antibodies and recombinant proteins, is emerging as the second highest performer, fueled by advancements in biotechnology. The integration of digital technologies and automation in manufacturing processes is enhancing efficiency and quality control. Strategic partnerships and collaborations among pharmaceutical companies and contract service providers are further driving innovation and market expansion.

The Pharmaceutical Contract Development and Manufacturing Market is experiencing a dynamic shift in market share, pricing, and new product launches. Key players are leveraging innovative technologies to enhance their offerings, resulting in a competitive landscape that is both challenging and rewarding. The emphasis on cost-effective and efficient manufacturing processes has led to a surge in new product introductions. Companies are strategically adjusting pricing models to capture a larger market share, catering to the evolving demands of the pharmaceutical industry. This market is characterized by a strong demand for specialized services, driving growth and innovation. Competition benchmarking in this sector reveals a landscape dominated by a few key players, with smaller firms striving to carve out niches through specialized services. Regulatory influences play a pivotal role, with stringent compliance requirements shaping operational strategies. North America and Europe hold significant sway over regulatory standards, impacting global market dynamics. Emerging markets in Asia-Pacific are witnessing increased activity, driven by favorable policies and investment in infrastructure. The competitive environment is further intensified by mergers and acquisitions, which are reshaping market boundaries and fostering innovation. This comprehensive analysis underscores the importance of strategic agility and regulatory compliance in navigating the complex pharmaceutical landscape.

Geographical Overview:

The Pharmaceutical Contract Development and Manufacturing Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains a dominant player, driven by advanced healthcare infrastructure and substantial investments in pharmaceutical R&D. The region's strong regulatory framework and high demand for innovative therapies bolster market growth. In Europe, the market is flourishing due to increased outsourcing by pharmaceutical companies seeking cost efficiencies. The region's established pharmaceutical industry and emphasis on biotechnology further enhance its appeal. Asia Pacific is emerging as a lucrative growth pocket, propelled by rising healthcare expenditures and expanding generic drug production. Countries like India and China are becoming pivotal hubs for pharmaceutical manufacturing, attracting significant foreign investments. Latin America and the Middle East & Africa are also gaining traction. Latin America benefits from a growing focus on healthcare access and affordability, while the Middle East & Africa are recognizing the potential of contract manufacturing in addressing regional healthcare needs and fostering economic development.

Global tariff policies and geopolitical tensions are significantly influencing the Pharmaceutical Contract Development and Manufacturing Market, particularly in East Asia. Japan and South Korea are enhancing their domestic capabilities to mitigate dependency on foreign suppliers, driven by rising tariffs and supply chain vulnerabilities. China, under export restrictions, is accelerating its focus on self-reliance, investing heavily in local pharmaceutical R&D and manufacturing. Taiwan, while a key player in pharmaceutical production, is navigating geopolitical pressures with strategic alliances. The global parent market is experiencing robust growth, propelled by increasing demand for outsourced drug development. By 2035, the market is anticipated to thrive on innovation and strategic partnerships. Middle East conflicts contribute to fluctuating energy prices, indirectly impacting manufacturing costs and global supply chain stability.

Key Trends and Drivers:

The pharmaceutical contract development and manufacturing market is experiencing robust growth, driven by escalating demand for biologics and biosimilars. This trend is fueled by the increasing prevalence of chronic diseases and the need for innovative therapeutic solutions. Biopharmaceutical companies are outsourcing development and manufacturing processes to enhance efficiency and focus on core competencies. Another significant trend is the rise of personalized medicine, which necessitates specialized production capabilities. Contract manufacturers are investing in advanced technologies to accommodate small-batch, high-precision manufacturing. The growing emphasis on quality and regulatory compliance is also a critical driver, prompting companies to partner with experienced contract manufacturers to navigate complex regulatory landscapes. Furthermore, the globalization of pharmaceutical supply chains is creating opportunities for contract development and manufacturing organizations to expand their footprint in emerging markets. As pharmaceutical companies seek to reduce costs and enhance flexibility, strategic partnerships with contract manufacturers are becoming increasingly vital. These collaborations are enabling faster time-to-market for new drugs, thereby driving market growth.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Small Molecules
  • 4.1.2 Biologics
  • 4.1.3 Advanced Therapy Medicinal Products
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Active Pharmaceutical Ingredients (APIs)
  • 4.2.2 Finished Dosage Forms (FDFs)
  • 4.2.3 Intermediates
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Formulation Development
  • 4.3.2 Process Development
  • 4.3.3 Analytical Services
  • 4.3.4 Clinical Manufacturing
  • 4.3.5 Commercial Manufacturing
  • 4.3.6 Packaging
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Lyophilization
  • 4.4.2 Spray Drying
  • 4.4.3 Nanotechnology
  • 4.4.4 Continuous Manufacturing
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Cardiology
  • 4.5.3 Neurology
  • 4.5.4 Infectious Diseases
  • 4.5.5 Immunology
  • 4.5.6 Respiratory
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Solid
  • 4.6.2 Liquid
  • 4.6.3 Semi-Solid
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Pharmaceutical Companies
  • 4.7.2 Biotechnology Companies
  • 4.7.3 Research Institutes
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Batch Manufacturing
  • 4.8.2 Continuous Manufacturing
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Preclinical
  • 4.9.2 Clinical
  • 4.9.3 Commercial

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Form
    • 5.2.1.7 End User
    • 5.2.1.8 Process
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Form
    • 5.2.2.7 End User
    • 5.2.2.8 Process
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Form
    • 5.2.3.7 End User
    • 5.2.3.8 Process
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Form
    • 5.3.1.7 End User
    • 5.3.1.8 Process
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Form
    • 5.3.2.7 End User
    • 5.3.2.8 Process
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Form
    • 5.3.3.7 End User
    • 5.3.3.8 Process
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Form
    • 5.4.1.7 End User
    • 5.4.1.8 Process
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Form
    • 5.4.2.7 End User
    • 5.4.2.8 Process
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Form
    • 5.4.3.7 End User
    • 5.4.3.8 Process
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Form
    • 5.4.4.7 End User
    • 5.4.4.8 Process
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Form
    • 5.4.5.7 End User
    • 5.4.5.8 Process
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Form
    • 5.4.6.7 End User
    • 5.4.6.8 Process
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Form
    • 5.4.7.7 End User
    • 5.4.7.8 Process
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Form
    • 5.5.1.7 End User
    • 5.5.1.8 Process
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Form
    • 5.5.2.7 End User
    • 5.5.2.8 Process
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Form
    • 5.5.3.7 End User
    • 5.5.3.8 Process
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Form
    • 5.5.4.7 End User
    • 5.5.4.8 Process
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Form
    • 5.5.5.7 End User
    • 5.5.5.8 Process
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Form
    • 5.5.6.7 End User
    • 5.5.6.8 Process
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Form
    • 5.6.1.7 End User
    • 5.6.1.8 Process
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Form
    • 5.6.2.7 End User
    • 5.6.2.8 Process
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Form
    • 5.6.3.7 End User
    • 5.6.3.8 Process
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Form
    • 5.6.4.7 End User
    • 5.6.4.8 Process
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Form
    • 5.6.5.7 End User
    • 5.6.5.8 Process
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Catalent
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Lonza
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Recipharm
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Patheon
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Wu Xi App Tec
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Siegfried Holding
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Piramal Pharma Solutions
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Fujifilm Diosynth Biotechnologies
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Cambrex Corporation
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Almac Group
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Vetter Pharma
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Boehringer Ingelheim Bio Xcellence
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Ajinomoto Bio- Pharma Services
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Samsung Biologics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Thermo Fisher Scientific
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Corden Pharma
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Fareva
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Hovione
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 AMRI
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Baxter Bio Pharma Solutions
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us